Regenerative drug development
The company develops novel regenerative drugs intended to have increased efficacy and reduced side-effects.
Source: LinkedIn company description · Retrieved October 13, 2026
Orio Therapeutics works to make regenerative medicine more accessible.
The company develops regenerative drugs and therapeutic proteins using targeted drug-delivery technologies. Its initial pipeline validation effort involves developing a therapeutic molecule for myocardial infarction.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company develops novel regenerative drugs intended to have increased efficacy and reduced side-effects.
Source: LinkedIn company description · Retrieved October 13, 2026
The company states that efficient drug delivery can be achieved through molecular designs rather than requiring complex devices and drug carriers.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Snapshot: September 18, 2026
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 14, 2026, September 18, 2026, September 19, 2026, September 20, 2026, September 21, 2026, September 26, 2026 and September 28, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.